Compare · DXCM vs IVF
DXCM vs IVF
Side-by-side comparison of DexCom Inc. (DXCM) and INVO Fertility Inc. (IVF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IVF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.50B, about 11602.4x IVF ($2.7M).
- DXCM has been more active in the news (6 items in the past 4 weeks vs 2 for IVF).
- DXCM has more recent analyst coverage (25 ratings vs 0 for IVF).
- Company
- DexCom Inc.
- INVO Fertility Inc.
- Price
- -
- -
- Market cap
- $31.50B
- $2.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest IVF
- Amendment: SEC Form SCHEDULE 13G/A filed by INVO Fertility Inc.
- INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
- SEC Form S-8 filed by INVO Fertility Inc.
- INVO Fertility Inc. filed SEC Form 8-K: Regulation FD Disclosure
- INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
- INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International
- INVO Fertility Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
- SEC Form 10-Q filed by INVO Fertility Inc.
- SEC Form 424B3 filed by INVO Fertility Inc.